DKN-01 and atezolizumab as second- or third-line therapy in advanced oesophagogastric adenocarcinoma: the WAKING trial

ESMO Gastrointestinal Oncology · Elsevier

Аннотация

Publication date: September 2026 Source: ESMO Gastrointestinal Oncology, Volume 13, Part B Author(s): A. Gordon, E. Cartwright, A. Tran, R. Crux, F. Turkes, E. Smyth, A. Smith, I. Manalang, I. Rana, D. Kohoutova, E. Johnston, A. Dunlop, M.S. Ul-Islam, S. Falk, A. Sita-Lumsden, S. Rao, N. Starling, I. Chau, D. Cunningham

Читать у издателя →

Похожие статьи